BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

N
Nabil Adra, MD

Primary Investigator

Overview

The purpose of this study is to study two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects.

Description

This is a prospective, 4 arm, multicenter, randomized, Phase II study in subjects with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects. This study will evaluate the use of two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects. The primary objective is to evaluate the objective PFS of abiraterone/prednisone, olaparib or the combination abiraterone/prednisone + olaparib in mCRPC patients with canonical DNA repair defects in BRCA1,BRCA2, or ATM.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    prostate cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Male

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Males 18 years or older
  • Diagnosis of Prostate Adenocarcinoma
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:
Participants will not be paid for their participation.

Updated on 07 Aug 2023. Study ID: 1708862929 (C16-168)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center